Navigation Links
Influenza study: Meet virus' new enemy
Date:2/21/2013

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers' methods of manipulating an enzyme that is key to how influenza replicates and spreads.

Their new compounds will lead to a new generation of anti-influenza drugs that the virus' strains can't adapt to, and resist, as easily as they do Tamiful. It's an anti-influenza drug that is becoming less effective against the constantly mutating flu virus.

These increasingly less adequate anti-influenza drugs are currently doctors' best weapons against influenza. They helped the world beat H1N1, swine flu, into submission four years ago.

The journal Science Express has just published online the scientists' study, revealing how to use their newly discovered compounds to interrupt the enzyme neuraminidase's facilitation of influenza's spread.

Tamiful and another anti-influenza drug, Relenza, focus on interrupting neuraminidase's ability to help influenza detach from an infected cell's surface by digesting sialic acid, a sugar on the surface of the cell. The flu virus uses the same sugar to stick to the cell while invading it. Once attached, influenza can invade the cell and replicate. v

This is where the newly discovered compounds come to the still-healthy cells' rescue. They clog up neuraminidase, stopping the enzyme from dissolving the sialic acid, which prevents the virus from escaping the infected cell and spreading.

The new compounds are also more effective because they're water-soluble. "They reach the patient's throat where the flu virus is replicating after being taken orally," says Niikura, a Faculty of Health Sciences associate professor.

"Influenza develops resistance to Replenza less frequently, but it's not the drug of choice like Tamiful because it's not water-soluble and has to be taken as a nasal spray.

"Our new compounds are structurally more similar to sialic acid than Tamiful. We expect this closer match will make it much more difficult for influenza to adapt to new drugs."

Ultimately, the new compounds will buy scientists more time to develop new vaccines for emerging strains of influenza that are resistant to existing vaccines.


'/>"/>

Contact: Carol Thorbes
cthorbes@sfu.ca
Simon Fraser University
Source:Eurekalert

Related biology news :

1. Target for potent first-strike influenza drugs identified
2. Climate change could increase levels of avian influenza in wild birds
3. Harnessing anticancer drugs for the future fight against influenza
4. Influenza research: Can dynamic mapping reveal clues about seasonality?
5. Pandemic controversies: The global response to pandemic influenza must change
6. BYU study: Using a gun in bear encounters doesnt make you safer
7. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
8. Study: Exercise can lead to female orgasm, sexual pleasure
9. U of I study: Lose body weight before gaining baby weight
10. Study: Men who do load-bearing exercise in early 20s may be shielded from osteoporosis
11. USF study: Common fungicide wreaks havoc on freshwater ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... , March 24, 2017 Agenus Inc. (NASDAQ: ... checkpoint antibodies and cancer vaccines, today announced participation at ... th  Annual William Blair and Maidstone Life Sciences conference ... Center in New York, NY . ... March 29 at 9:40 am: Robert B. Stein ...
(Date:3/23/2017)... ... 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking ... for companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 ... increasing popularity is due to its new team building format, a way for teams to ...
(Date:3/23/2017)...  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a ... solid tumor cancers, today announced that yesterday it ... last Friday, March 17, 2017. ... totaling 28,843,692 shares, comprised of 18,843,692 common shares ... Class C Warrants pre-funded at the closing at ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
Breaking Biology Technology: